Clarity in DTC TV ad drug pricing
Belle Frank is chief strategy officer, global health practice at VMLY&R.
Drug Pricing
Johnson & Johnson to put list prices in TV drug ads
The drugmaker will add list prices to ads for Xarelto by the end of March.
Was President Trump’s plan to reduce drug prices DOA?
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Cassidy, Warner draft bill to promote value-based payment models
Senators Bill Cassidy and Mark Warner are taking feedback from the public before introducing the bill.
The next five years of pharma: Pricing, biosimilars, and specialty medicines
A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
‘The current system is flawed’: PhRMA’s Zirkelbach on pricing
Robert Zirkelbach, public affairs EVP at PhRMA, discussed the group’s legislative priorities at the Coalition for Healthcare Communication’s post-election conference on Tuesday.
Pfizer to resume price increases in January
The drugmaker will raise prices on 10% of its drug portfolio.
How to lower drug prices in the U.S.? Lots of suggestions, few viable solutions
A panel representing pharma, government payer, and policy analyst presented three potential big-picture goals to strive for.
Five things for pharma marketers to know: Monday, September 10, 2018
U.K. regulator rules MS drug too expensive; Memorial Sloan Kettering CEO demands more transparency from staff on financial relationships; Report: Family behind Purdue owns second opioid drugmaker.
Five things for pharma marketers to know: Friday, August 24, 2018
White House proposes rule for drug prices in DTC ads; FDA to study impact of side-effects warnings in drug ads; FDA approves Shire’s potential blockbuster HAE treatment.
